NFKB1 and triple-A syndrome: Although immune-suppressive treatment should be carefully evaluated [46], selectively inhibiting NF-kB signaling in activated and proliferating lymphocytes in dysfunctional AAA PVAT may be a targeted therapeutic intervention without compromising the healthy effect mediated by NF-kB in other immune cells.